Cytokinetics, Inc.
Cytokinetics Reports Second Quarter 2025 Financial Results
Summary
Cytokinetics, Incorporated announced its financial results for the second quarter of 2025, revealing a significant increase in total revenues to $66.8 million, primarily due to a $52.4 million recognition from the license and collaboration agreement with Bayer for aficamten in Japan. The company reported a net loss of $134.4 million for the quarter, and maintains its full-year 2025 financial guidance. The primary focus remains on preparations for the potential FDA approval of aficamten in late December 2025, and the company is also advancing its clinical trials for aficamten and other drug candidates.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement